

## Efficacy and safety of roxadustat for treatment of anemia in patients with lower risk MDS with low red blood cell transfusion burden


**Population:** N = 24

**Primary endpoint:** Proportion of patients with transfusion independence (TI) for ≥8 consecutive weeks in the first 28 treatment weeks **Eligibility:** Baseline serum erythropoietin ≤400 mIU/mL and a low packed RBC transfusion burden

### TRIAL DESIGN Intervention







## **EFFICACY**

# **Primary** endpoint

TI for ≥8 consecutive weeks



28 weeks



52 weeks

#### Mean duration of TI

26.1 weeks TI for ≥8 weeks

TI for ≥20 weeks

46.3 weeks

# TI by baseline ring sideroblasts or erythropoietin levels



MDS-RS+ (n = 13)



MDS-RS-(n = 11)



(n = 18)

≤200 mIU/mL 200-400 mIU/mL (n = 6)

**TI responders** by starting dose

1.5 mg/kg (n = 8)	37.5%
2.0 mg/kg (n = 8	12.5%
2.5 mg/kg (n = 8 <mark>)</mark>	62.5%
Overall (n = 24)	37.5%

### SAFETY

TEAEs	87.5%
Serious TEAEs	33.3%
TEAEs loading to discontinus	tion 4 20/

### Most common TEAEs (any grade):



Diarrhea



Henry HD, et al. Am J Hematol. 2021. Online ahead of print. DOI: 10.1002/ajh.26397



